Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling. This is an ASCO Meeting Abstract from the 2023 ...
PD-L1 × TIGIT × LAG3 format enables simultaneous interrogation of three complementary checkpoint pathways within a single in ...
Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but ...
Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. The authors of a new article published in Acta Pharmaceutica Sinica B describe ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results